Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 25;9:1034. doi: 10.3389/fonc.2019.01034

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Hlavackova, Pilatova, Cerna, Selingerova, Mudry, Mazanek, Fedorova, Merhautova, Jureckova, Semerad, Pacasova, Flajsarova, Souckova, Demlova, Sterba, Valik and Zdrazilova-Dubska.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Treatment prior to monocyte harvest and immunostimulatory properties of manufactured DCs. Manufacturing subgroup from monocytes harvested after MTD-based therapy potentially interfering with monocyte biology (listed in Supplementary Table 1; “m” treatment, gray box plots) and manufacturing subgroup from monocytes from untreated patients or after non-interfering treatment (“0” treatment, white box plots) were compared based on QC parameters: (A) IL-12 production, (B) IL-12/IL-10 production ratio, (C) allo-MLR and (D) auto-MLR. Median values are shown for each parameter for each treatment subgroup. Black dots show QC results of manufactured DCs that passed quality control, and red dots show results of manufactured DCs that did not pass quality control.